Breast Cancer, Breast Cancer Female
Conditions
Brief summary
This is a prospective, single center, single arm phase II study designed to explore the efficacy and safety of surufatinib + fulvastrant + chidamide combinational treatment in HR positive breast cancer refractory to endocrine therapy.
Detailed description
This is a prospective, single center, single arm phase II study. In the safety lead-in stage, 6 subjects will be recruited and administered with surufatinib 250 mg/d, QD PO; Fulvestrant 500mg, im, Q4W; Chidamide 30mg, PO, BIW, with four weeks as a cycle. DLTs of the 6 subjects will be evaluated in the first cycle to determine the recommended dosage of combinational therapy. Then 57 subjects will be recruited and administered with the triplet regimen to explore the efficacy and safety of combinational treatment.
Interventions
DRUGsurufatinib + fulvestrant + chidamide
surufatinib: 250 mg/d, QD PO; Fulvestrant: 500mg, im, Q4W; Chidamide 30mg, PO, BIW; Q4W
Sponsors
The First Affiliated Hospital of Zhengzhou University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Signed the Informed Consent Form; * 18-75 Years (concluding 18 and 75 Years), female; * Pathologically and cytologically confirmed non-resectable stage IV Her2 negative, HR positive (ER+ and / or PR+) breast cancer; * Relapsed or progressed after at least first-line endocrine therapy, with patients of primary endocrine resistance excluded (patients of recurrence and metastasis progressed more than 6 months after receiving endocrine therapy or more than 2 years after receiving adjuvant endocrine therapy are eligible; patients progressed more than 1 year but less than 2 years after adjuvant endocrine therapy are not eligible); * 2 weeks or more from the last endocrine therapy and 3 weeks or more from the last chemotherapy before enrollment; * At least one measurable lesion is required; * Life expectancy greater than 3 months; * ECOG(Eastern Cooperative Oncology Group): 0\ 1; * Sufficient organ and bone marrow functions as follows: Absolute Neutrophil Count (ANC) ≥1.5×10\^9/L; Platelet Count of ≥100×10\^9/L; Hemoglobin≥90g/L; Total Bilirubin (TBIL)\<1.5 x ULN; ALT and AST\<1.5 x ULN; Serum Creatinine (SCr)\<1.5×ULN; Endogenous creatinine clearance rate ≥50ml / min (Cockcroft Gault formula)
Exclusion criteria
* Previous treatment with VEGFR inhibitor, HDAC inhibitor or fulvestrant; * Organ surgery performed 6 weeks before enrollment; * A history of other malignancies within 5 years prior to enrollment, except for cervical carcinoma in situ, basal or squamous cell skin cancer; * Known hypersensitivity to any of the study drugs or excipients; * Hypertension that is not controlled by the drug, and is defined as: SBP ≥150 mmHg and/or DBP ≥90 mmHg; * International normalized ratio (INR) \> 1.5 or partially activated prothrombin time (APTT) \> 1.5 × ULN; * Poorly controlled diabetes before enrollment; * Clinically significant electrolyte abnormalities judged by researchers; * With any diseases or conditions that affected drug absorption, or the patient could not take drugs orally; * Patients with obvious evidence of bleeding tendency or medical history or hemoptysis within 3 months before enrollment, thromboembolism within 12 months; * Cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe / unstable angina pectoris or coronary artery bypass grafting within 6 months before enrollment; Congestive heart failure, New York Heart Association (NYHA) grade \> 2; ventricular arrhythmia requiring drug treatment; LVEF (left ventricular ejection fraction) \< 50%; * Active infection or serious infection that is not controlled by drug (≥CTCAE v5.0 Grade 2）; * History of clinically significant hepatic disease, including, but not limited to, known hepatitis B virus (HBV) infection with HBV DNA positive (copies ≥1×10\^4/ml); known hepatitis C virus infection with HCV RNA positive (copies ≥1×10\^3/m); * Women who are pregnant or lactating; * Urinary protein ≥ ++, and the 24-hour urine protein quantification is greater than 1.0g; * Have any other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other conditions, which according to the judgment of the investigator, it is reasonable to suspect that the patient is not suitable for the use of the study drug.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | up to 3 years | PFS was defined as the time from recruitment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | up to 3 years | The proportion of patients with a confirmed complete response or partial response on two consecutive occasions≥4 weeks apart. |
| DCR | up to 3 years | The proportion of patients with a best overall response of confirmed complete or partial response, or stable disease (CR+ PR + SD). |
| OS | up to 3 years | The time from recruitment to death due to any cause. |
| Adverse Events (AEs) | up to 3 years | Adverse events (AEs) categorized by severity in accordance with the NCI CTC AE Version 5.0. |
Countries
China
Contacts
Primary ContactHong Zong, M.D.
Outcome results
None listed